Category: News & Comments
Aerie’s successful new confirmatory study for Rhopressa® was a necessity
Aerie Pharmaceuticals (AERI) announced results from a double-masked, randomized, placebo-controlled study designed to evaluate the effect of its glaucoma product Rhopressa ® (netarsudil ophthalmic solution ) 0.02% on aqueous humor dynamics in patients with open-angle glaucoma or ocular hypertension. This...
Read More
August 15, 2018
0
Why Celyad’s stock gained $2.30 today
Celyad (CYAD) is an immuno-oncology firm, which created CAR T CELL treatments for cancers, including solid tumors. Celyad announced its consolidated financial results for the six-month period ending 30 June 2018. Celyad’s report is endorsed by Europe. Dr. Christian Homsy, Celyad’s...
Read More
August 23, 2018
0
About Exelixis' Transition
EXELIXIS Exelixis’ (EXEL) shareholders know well how good are the firm’s announced financial results for the second quarter of 2017. They also know well how good is the update presented by the firm about the progress made towards fulfilling its...
Read More
August 8, 2017
0
Merck's product Keytruda and Exelixis' product Cabometyx are both winners
Keytruda and Cabometyx Are Both Winners Keytruda failed to meet co-primary endpoints in Pivotal Phase 3 trial The pivotal Phase 3 KEYNOTE-240 trial evaluating Keytruda, Merck’s ( MRK ) checkpoint inhibitor anti-PD-1 therapy plus best supportive care, for the treatment...
Read More
February 21, 2019
0
Spark Therapeutics to be acquired by Roche at $113.47 UP $61.91
We congratulate our subscribers who kept Spark Therapeutics ( ONCE ) in spite of the stock’s kind of paralysis for no serious reasons. Spark, a fully integrated, commercial gene therapy company, announced today that it has entered into a definitive merger agreement...
Read More
February 25, 2019
0
When all the prophets are taken by surprise
When the Goal is Reaching into the Future, Pessimists Have No Place on the Ship The revolution in the biotech sector has proven to be moving fast towards reaching goals that were impossible to imagine a couple of years ago...
Read More
August 24, 2018
0
PTC Therapeutics now with a wealthier pipeline
Before we sell PTC Therapeutics (PTCT) , after the stock had reached and surpassed our latest and highest 2018 target, the firm did the right thing that we expected was good enough to encourage investment in this firm. The good...
Read More
August 28, 2018
0
RegenxBio has good news
We reiterate that undeniably outstanding news about gene therapy is taking time to penetrate investors’ ears. They are still falling victim to bad rules of thumb and critics’ magnifications of the negative impact of some stocks’ dilution when companies with...
Read More
August 30, 2018
0
Why Scientists Are Now Optimistic Zeroing in on Neurodegenerative Diseases
New Discoveries in Neurodegenerative Diseases Everyday is another day that can totally differ from the previous day with regard to increasing researchers’ capabilities of discovering new pathways of diseases and turning their new discoveries into far-reaching treatments. The tireless revolution...
Read More
August 24, 2017
0
Xoma: A Rally for Good Reasons
Xoma (XOMA) stock rallied surprising many but not all. We put this firm in a special table called aggressive portfolio where we put of firms with strong scientific and technological fundamentals that, for bad reasons, or trials and errors reasons...
Read More
August 25, 2017
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)